{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T07:35:38Z","timestamp":1763105738404,"version":"build-2065373602"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T00:00:00Z","timestamp":1589414400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013489","name":"Yakult Pharmaceutical Industry Co","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013489","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical Co","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.tjog.2020.05.013","type":"journal-article","created":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T10:54:59Z","timestamp":1594205699000},"page":"546-550","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Nedaplatin use in patients with hypersensitivity reaction episodes to carboplatin"],"prefix":"10.1016","volume":"59","author":[{"given":"Kenro","family":"Chikazawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachiho","family":"Netsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya","family":"Ishiguro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azusa","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangcheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Kuwata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Konno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tjog.2020.05.013_bib1","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.2004.05.195","article-title":"Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design","volume":"22","author":"Markman","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.tjog.2020.05.013_bib2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/ijgc-00009577-200505001-00007","article-title":"Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer","volume":"15","author":"Pfisterer","year":"2005","journal-title":"Int J Gynecol Canc"},{"key":"10.1016\/j.tjog.2020.05.013_bib3","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","article-title":"Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse","volume":"28","author":"Pujade-Lauraine","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.tjog.2020.05.013_bib4","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1200\/JCO.2014.58.4391","article-title":"Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505","volume":"33","author":"Kitagawa","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.tjog.2020.05.013_bib5","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1200\/JCO.1999.17.4.1141","article-title":"Clinical features of hypersensitivity reactions to carboplatin","volume":"17","author":"Markman","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.tjog.2020.05.013_bib6","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/IGC.0b013e3181a1bf2e","article-title":"Incidence of carboplatin-related hypersensitivity reactions in Japanese patients with gynecologic malignancies","volume":"19","author":"Koshiba","year":"2009","journal-title":"Int J Gynecol Canc"},{"key":"10.1016\/j.tjog.2020.05.013_bib7","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s002800050604","article-title":"In\u00a0vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers","volume":"39","author":"Alberts","year":"1997","journal-title":"Canc Chemother Pharmacol"},{"key":"10.1016\/j.tjog.2020.05.013_bib8","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1006\/gyno.1998.5140","article-title":"In\u00a0vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human cervical cancers","volume":"71","author":"Monk","year":"1998","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2020.05.013_bib9","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1447-0756.2012.01893.x","article-title":"Safety and efficacy of substituting nedaplatin after carboplatin hypersensitivity reactions in gynecologic malignancies","volume":"39","author":"Michikami","year":"2013","journal-title":"J\u00a0Obstet Gynaecol Res"},{"key":"10.1016\/j.tjog.2020.05.013_bib10","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1447-0756.2012.01917.x","article-title":"Retreatment with nedaplatin in patients with recurrent gynecological cancer after the development of hypersensitivity reaction to carboplatin","volume":"39","author":"Arimoto","year":"2013","journal-title":"J\u00a0Obstet Gynaecol Res"},{"key":"10.1016\/j.tjog.2020.05.013_bib11","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.3892\/ol.2012.853","article-title":"Nedaplatin and irinotecan combination therapy is equally effective and less toxic than cisplatin and irinotecan for patients with primary clear cell adenocarcinoma of the ovary and recurrent ovarian carcinoma","volume":"4","author":"Machida","year":"2012","journal-title":"Oncol Lett"},{"key":"10.1016\/j.tjog.2020.05.013_bib12","first-page":"3646","article-title":"Paclitaxel plus nedaplatin vs. paclitaxel plus carboplatin in women with epithelial ovarian cancer: a multi-center, randomized, open-label, phase III trial","volume":"15","author":"Li","year":"2018","journal-title":"Oncol Lett"},{"key":"10.1016\/j.tjog.2020.05.013_bib13","first-page":"1074","article-title":"Nedaplatin and paclitaxel compared with carboplatin and paclitaxel for patients with platinum-sensitive recurrent ovarian cancer","volume":"8","author":"Ge","year":"2018","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.tjog.2020.05.013_bib14","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ygyno.2012.05.010","article-title":"Phase II trial of paclitaxel and nedaplatin in patients with advanced\/recurrent uterine cervical cancer: a Kansai Clinical Oncology Group study","volume":"126","author":"Takekuma","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2020.05.013_bib15","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.tjog.2020.05.013_bib16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ygyno.2013.07.100","article-title":"Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"131","author":"Burger","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2020.05.013_bib17","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.tjog.2020.05.013_bib18","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ygyno.2011.04.019","article-title":"Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial","volume":"122","author":"Joly","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2020.05.013_bib19","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1200\/JCO.2017.73.4293","article-title":"Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer: the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study","volume":"35","author":"Pignata","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.tjog.2020.05.013_bib20","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.tjog.2018.10.009","article-title":"Bevacizumab improves overall survival in platinum refractory ovarian cancer patients: a retrospective study","volume":"57","author":"Chikazawa","year":"2018","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2020.05.013_bib21","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.tjog.2020.05.013_bib22","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.tjog.2017.08.026","article-title":"Poly (ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer","volume":"56","author":"Liu","year":"2017","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2020.05.013_bib23","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.tjog.2020.05.013_bib24","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.ajog.2013.10.883","article-title":"The retreatment of carboplatin via high-dose intraperitoneal chemotherapy in patients with a history of a hypersensitivity reaction","volume":"210","author":"Rettenmaier","year":"2014","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2020.05.013_bib25","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1006\/gyno.2001.6519","article-title":"Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy","volume":"84","author":"Dizon","year":"2002","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2020.05.013_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2007.04.044","article-title":"Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer","volume":"197","author":"Callahan","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2020.05.013_bib27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1006\/gyno.1994.1098","article-title":"Death from anaphylaxis to cisplatin: a case report","volume":"53","author":"Zweizig","year":"1994","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2020.05.013_bib28","first-page":"108","article-title":"A\u00a0new rapid desensitization protocol for chemotherapy agents","volume":"21","author":"Gastaminza","year":"2011","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.tjog.2020.05.013_bib29","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0090-8258(03)00178-1","article-title":"Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity","volume":"89","author":"Rose","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2020.05.013_bib30","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1006\/gyno.2001.6331","article-title":"Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies","volume":"82","author":"Robinson","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2020.05.013_bib31","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1006\/gyno.2001.6513","article-title":"Hypersensitivity reactions to carboplatin","volume":"84","author":"Markman","year":"2002","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2020.05.013_bib32","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/IGC.0b013e3181a418ff","article-title":"Carboplatin hypersensitivity: does introduction of skin test and desensitization reliably predict and avoid the problem? A prospective single-center study","volume":"19","author":"Gomez","year":"2009","journal-title":"Int J Gynecol Canc"},{"key":"10.1016\/j.tjog.2020.05.013_bib33","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.jaci.2009.02.042","article-title":"Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management","volume":"123","author":"Hesterberg","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.tjog.2020.05.013_bib34","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/cncr.21168","article-title":"Successful carboplatin desensitization in patients with proven carboplatin allergy","volume":"104","author":"Confino-Cohen","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.tjog.2020.05.013_bib35","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ygyno.2005.06.028","article-title":"Rapid inpatient\/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses","volume":"99","author":"Lee","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2020.05.013_bib36","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S1081-1206(10)61465-2","article-title":"Carboplatin desensitization","volume":"93","author":"Choi","year":"2004","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.tjog.2020.05.013_bib37","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0090-8258(03)00541-9","article-title":"A\u00a0case of prolonged carboplatin therapy in a patient with carboplatin hypersensitivity","volume":"91","author":"McElroy","year":"2003","journal-title":"Gynecol Oncol"}],"container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455920301121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455920301121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T18:18:58Z","timestamp":1760897938000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1028455920301121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S1028455920301121"],"URL":"https:\/\/doi.org\/10.1016\/j.tjog.2020.05.013","relation":{},"ISSN":["1028-4559"],"issn-type":[{"type":"print","value":"1028-4559"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nedaplatin use in patients with hypersensitivity reaction episodes to carboplatin","name":"articletitle","label":"Article Title"},{"value":"Taiwanese Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjog.2020.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Taiwan Association of Obstetrics & Gynecology. Publishing services by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}